22Z Stock Overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Zealand Pharma A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.96.25 |
52 Week High | kr.103.40 |
52 Week Low | kr.27.20 |
Beta | 0.68 |
1 Month Change | 50.86% |
3 Month Change | 93.04% |
1 Year Change | 216.82% |
3 Year Change | 257.54% |
5 Year Change | 494.50% |
Change since IPO | 946.99% |
Recent News & Updates
Recent updates
Shareholder Returns
22Z | DE Biotechs | DE Market | |
---|---|---|---|
7D | 2.0% | 3.3% | 1.6% |
1Y | 216.8% | 35.8% | 6.4% |
Return vs Industry: 22Z exceeded the German Biotechs industry which returned 35.3% over the past year.
Return vs Market: 22Z exceeded the German Market which returned 6.4% over the past year.
Price Volatility
22Z volatility | |
---|---|
22Z Average Weekly Movement | 16.6% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 22Z's share price has been volatile over the past 3 months.
Volatility Over Time: 22Z's weekly volatility has increased from 10% to 17% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 253 | Adam Steensberg | https://www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
22Z fundamental statistics | |
---|---|
Market cap | €5.86b |
Earnings (TTM) | -€94.36m |
Revenue (TTM) | €45.96m |
127.5x
P/S Ratio-62.1x
P/E RatioIs 22Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
22Z income statement (TTM) | |
---|---|
Revenue | kr.342.79m |
Cost of Revenue | kr.688.10m |
Gross Profit | -kr.345.31m |
Other Expenses | kr.358.43m |
Earnings | -kr.703.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
Earnings per share (EPS) | -11.31 |
Gross Margin | -100.74% |
Net Profit Margin | -205.30% |
Debt/Equity Ratio | 0% |
How did 22Z perform over the long term?
See historical performance and comparison